Specifications - Tykerb - Dual Tyrosine Kinase Inhibitor for the Treatment of Solid Tumours

Key Data
Drug (Brand/Generic)	Tykerb/Tyverb/Lapatinib ditosylate
Company/Licensee	GlaxoSmithKline
Therapy Class	TKI
Product Description	Dual-acting TKI that targets erbB1 and erbB2
Current Indication	Breast cancer
Market Sector	Oncology
Development Status	Approved US and Europe